Tissue Regenix Group plc EBIT

Tissue Regenix Group plc (TSSNF) currently reports a EBIT of $-500K as of June 2024. That compares with $-11M in the prior-year period — up 95.6% year over year. That is above the sector sector average of $-26M. Use the charts on this page to explore Tissue Regenix Group plc's EBIT history and peer comparisons.

Tissue Regenix Group plc's EBIT increased from $-11M to $-500K — a 95.6% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tissue Regenix Group plc's EBIT of $-500K is higher than the its sector sector average of $-26M. That is roughly 98.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Tissue Regenix Group plc reported $-500K in EBIT as of June 2024. That compares with $-11M in the prior-year period — up 95.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-500K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-26M. From there, open related valuation or income-statement pages for Tissue Regenix Group plc, and consider following TSSNF for alerts when major investors trade the stock.